Vivus Inc (VVUS) 1.05 $VVUS VIVUS Extends Retur
Post# of 273258
Posted On: 09/02/2016 7:09:11 PM
Vivus Inc (VVUS) 1.05 $VVUS
VIVUS Extends Return Date of STENDRA Commercial Rights
Marketwired - Mon Aug 29, 3:30PM CDT
VIVUS and Auxilium Agree to Extend the STENDRA(R) (avanafil) U.S. and Canadian License Agreement Through September 30, 2016
VVUS: 1.05 (-0.01)
VIVUS Reports 2016 Second Quarter Financial Results
Marketwire Canada - Thu Aug 04, 3:15PM CDT
Management to Review Results and Provide Business Update in Conference Call Today at 4:30 p.m. Eastern Time
VVUS: 1.05 (-0.01)
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Marketwired - Wed Jul 27, 3:16PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 27, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.
VVUS: 1.05 (-0.01)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.96 (-0.18), BIIB: 313.59 (+7.56), VVUS: 1.05 (-0.01), PTCT: 7.91 (+0.12)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.86 (-0.06), RTRX: 16.10 (-0.25), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.05 (-0.01)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.05 (-0.01)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (-0.02), INO: 9.08 (-0.06), VVUS: 1.05 (-0.01), TEVA: 51.22 (+0.32), ARNA: 1.57 (+0.01), PBYI: 57.48 (-1.23)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 6.32 (-0.13), JAZZ: 120.84 (-2.47), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)
Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.05 (-0.01)
Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"
, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016.
VVUS: 1.05 (-0.01)
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.01)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 1.02 (unch), VVUS: 1.05 (-0.01), PETX: 8.81 (-0.11), GALE: 0.40 (unch)
VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.05 (-0.01)
Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.70 (-0.05), SKYS: 2.87 (-0.01), VVUS: 1.05 (-0.01), GNCA: 5.37 (+0.09)
VIVUS Extends Return Date of STENDRA Commercial Rights
Marketwired - Mon Aug 29, 3:30PM CDT
VIVUS and Auxilium Agree to Extend the STENDRA(R) (avanafil) U.S. and Canadian License Agreement Through September 30, 2016
VVUS: 1.05 (-0.01)
VIVUS Reports 2016 Second Quarter Financial Results
Marketwire Canada - Thu Aug 04, 3:15PM CDT
Management to Review Results and Provide Business Update in Conference Call Today at 4:30 p.m. Eastern Time
VVUS: 1.05 (-0.01)
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Marketwired - Wed Jul 27, 3:16PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 27, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.
VVUS: 1.05 (-0.01)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.96 (-0.18), BIIB: 313.59 (+7.56), VVUS: 1.05 (-0.01), PTCT: 7.91 (+0.12)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.86 (-0.06), RTRX: 16.10 (-0.25), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.05 (-0.01)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.05 (-0.01)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (-0.02), INO: 9.08 (-0.06), VVUS: 1.05 (-0.01), TEVA: 51.22 (+0.32), ARNA: 1.57 (+0.01), PBYI: 57.48 (-1.23)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 6.32 (-0.13), JAZZ: 120.84 (-2.47), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)
Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.05 (-0.01)
Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"
, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016. VVUS: 1.05 (-0.01)
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.01)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 1.02 (unch), VVUS: 1.05 (-0.01), PETX: 8.81 (-0.11), GALE: 0.40 (unch)
VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.05 (-0.01)
Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.70 (-0.05), SKYS: 2.87 (-0.01), VVUS: 1.05 (-0.01), GNCA: 5.37 (+0.09)
(0)
(0)Scroll down for more posts ▼